Ascorbic acid, Corticosteroids and Thiamine in Sepsis Study (ACTS)
Please click here for more detailed information about the study
Description: a randomized, double-blind, placebo-controlled trial of ascorbic acid, hydrocortisone, and thiamine to improve outcomes in septic shock.
Michael W. Donnino (Principal Investigator)
Ari Moskowitz MD
Katherine M. Berg MD
Michael N. Cocchi MD
Anne V. Grossestreuer PhD
Paul Marik, MD
Lars W. Andersen, MD, MPH, PhD
Status of Study:
Purpose of Protocol:
Our overall hypothesis is that the administration of ascorbic acid, hydrocortisone, and thiamine in septic shock patients will mitigate organ injury through improvement in free radical reduction, immune function, endothelial integrity, and mitochondrial energy production.
Specific Aim – To determine whether the combination of thiamine/ascorbic acid/hydrocortisone administered to patients with shock septic mitigates organ dyfunction as compared to placebo.
Significance and Background:
Septic shock is a common and highly morbid condition affecting over 200,000 patients in the United States each year and resulting in upwards of 40,000 deaths. In-hospital mortality for patients admitted with septic shock has been has been estimated to be as high as 40%. While there is presently no recommended pharmacologic therapy specifically targeted at attenuating organ injury in septic shock, recent observational studies have found promising results using the combination of ascorbic acid (vitamin C), corticosteroids, and thiamine (vitamin B1). This medication combination has gained traction in the lay-media and is already being used by some hospitals to treat patients with sepsis and septic shock. Prospective testing in a randomized controlled trial, however, is needed prior to the widespread implementation of this therapy for victims of septic shock.
This prospective, randomized, blinded, placebo-controlled multi-center trial will investigate the effect of ascorbic acid, hydrocortisone, and thiamine vs placebo on organ function in patients with septic shock. We will also evaluate other outcomes including mortality.
|Henry Ford Hospital||Detroit, MI|
|DMC-Detroit Receiving Hospital||Detroit, MI|
|DMC-Sinai-Grace Hospital||Detroit, MI|
|Harper Hospital||Detroit, MI|
|UT Health, The University of Texas Health Science Center||Houston, TX|
|Mayo Clinic||Phoenix, AZ|
|Beaumont Hospital||Royal Oak, MI|
|Brigham and Women’s Hospital||Boston, MA|
|Long Island Jewish Hospital Center - Queens||New York, NY|
|Long Island Jewish Hospital Center – Hyde Park||New York, NY|
|Mount Auburn Hospital||Cambridge, MA|
|University of Pittsburgh||Pittsburgh, PA|
|South Shore Hospital||South Shore, MA|
- Adult (≥ 18 years)
- Suspected (blood cultures drawn and antibiotics given) or confirmed (via culture results) infection
- Receiving vasopressor support (norepinephrine, phenylephrine, epinephrine, dopamine, or vasopressin)*Sepsis/Infection should be the suspected precipitant of hypotension requiring vasopressor support.
- Known kidney stones within the past 1 year (not including incidentally noted stones)
- End Stage Renal Disease requiring renal replacement therapy
- Known G6PD deficiency or hemochromatosis
- Comfort Measures Only status or anticipated death within 24-hours despite maximal therapy
- Clinical indication for steroids, thiamine, or Vitamin C as determined by clinical teams
- Known allergy to vitamin C, hydrocortisone, or thiamine
- Protected Population (prisoner, pregnant)
All patients will receive standard septic shock care per their clinical team, whether or not they enroll in the study. After consent/enrollment, patients will have baseline labs drawn, and will be administered the study drug or placebo four times daily for four days (or until they leave the ICU).
Blood and Urine sample collection: All patients will have blood samples collected at 0, 24, 72, and 120 hours, with testing as detailed below.
Primary Outcome: The primary outcome will be the Sequential Organ Failure Assessment (SOFA) score. The SOFA score is a measure of organ dysfunction.
- Need for renal replacement therapy
- Incidence of delirium
- Vasopressor-free days
- Ventilator-free days
- ICU LOS
- 30-day Mortality
- 90-day cognitive outcomes
- Measurements of other blood and urine marker of organ dysfunction